Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
- Posted on August 20, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.
